PI
PMVP icon

PEAK6 Investments’s PMV Pharmaceuticals PMVP Stock Holding History

PEAK6 Investments’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,000
Closed -$178K – 5046
2022
Q3 		$178K Hold
15,000
– – ﹤0.01% 3755
2022
Q2 		$214K Buy
+15,000
New +$218K ﹤0.01% 4700

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PEAK6 Investments's PMVP Position: Q4 2023 in Review

PEAK6 Investments sold out of PMV Pharmaceuticals (PMVP) in Q4 2023, closing a stake of 32,500 shares — an estimated $200K sold.

PEAK6 Investments first reported a position in PMVP in Q3 2023 and held it in 1 quarter. The position peaked at $200K in Q3 2023. 98 funds tracked by Wall St. Rank hold PMVP as of Q4 2023.

  • PEAK6 Investments reported no remaining PMV Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • PEAK6 Investments sold 32,500 PMV Pharmaceuticals shares in Q4 2023, an estimated $200K.
  • PEAK6 Investments first reported a position in PMV Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • PEAK6 Investments's PMV Pharmaceuticals position peaked at $200K in Q3 2023.
  • 98 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2023.

Based on PEAK6 Investments's 13F filing for Q4 2023, filed 13 Feb 2024.